33236-61-2Relevant academic research and scientific papers
Controlling stereoselectivity by enzymatic and chemical means to access enantiomerically pure (1S,3R)-1-benzyl-2,3-dimethyl-1,2,3,4- tetrahydroisoquinoline derivatives
Orden, Alejandro A.,Schrittwieser, Joerg H.,Resch, Verena,Mutti, Francesco G.,Kroutil, Wolfgang
, p. 744 - 749 (2013/07/25)
A chemoenzymatic strategy for the synthesis of enantiomerically pure novel alkaloids (1S,3R)-1-benzyl-2,3-dimethyl-1,2,3,4-tetrahydroisoquinolines is presented. The key steps are the biocatalytic stereoselective reductive amination of substituted 1-phenyl
Synthesis and in vitro cytotoxicity profile of the R-enantiomer of 3,4-dihydroxymethamphetamine (R-(-)-HHMA): Comparison with related catecholamines
Felim, Anne,Herrera, Guadalupe,Neudoerffer, Anne,Blanco, Manuel,O'Connor, Jose-Enrique,Largeron, Martine
experimental part, p. 211 - 219 (2011/02/22)
(±)-3,4-Methylenedioxymethamphetamine (MDMA, also known as "ecstasy") is a chiral drug that is essentially metabolized in humans through O-demethylenation into 3,4-dihydroxymethamphetamine (HHMA). There has recently been a resurgence of interest in the po
Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs
-
Page 8; 22, (2008/06/13)
The present invention comprises novel analogs of ecstasy-class compounds and novel ecstasy-class immunogens leashed out of, i.e., derived from, the methylenedioxy position. The invention also comprises unique monoclonal antibodies generated using MDO-leashed MDMA immunogens as well as unique conjugates and tracers. These antibodies, conjugates, and tracers are useful in immunoassays for the detection of ecstasy-class compounds in biological fluids.
